Mega Lifesciences PCL Balance Sheet

Financials in millions THB. Fiscal year is January - December.

Millions THB. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	4,637	4,273	3,463	2,357	2,453	2,198
Short-Term Investments	-	370.96	395.19	365.05	345.55	342.64
Cash & Short-Term Investments	4,637	4,644	3,858	2,722	2,799	2,540
Cash Growth	18.62%	20.37%	41.74%	-2.76%	10.18%	106.14%
Accounts Receivable	3,300	3,306	2,975	3,314	3,107	2,557
Other Receivables	-	143.66	152.53	158.28	180.15	164.18
Receivables	3,300	3,450	3,128	3,472	3,287	2,721
Inventory	3,259	3,038	3,033	3,377	4,109	3,823
Prepaid Expenses	-	58.79	60.43	58.59	60.14	53.43
Other Current Assets	446	162.24	147.7	360.23	334.95	162.8
Total Current Assets	11,642	11,353	10,227	9,990	10,590	9,301
Property, Plant & Equipment	2,323	2,409	2,213	2,225	2,151	2,103
Long-Term Investments	-	37.22	40.39	221.15	222.88	214.79
Goodwill	-	428.51	449	456.24	465.88	476.25
Other Intangible Assets	1,326	867.17	869.72	862.23	863.31	876.89
Long-Term Deferred Tax Assets	376.5	375.3	299.89	278.95	250.32	210.41
Other Long-Term Assets	362.4	289.03	111.52	81	103.49	89.75
Total Assets	16,030	15,759	14,210	14,115	14,646	13,272
Accounts Payable	1,884	1,720	1,685	1,925	2,793	2,527
Accrued Expenses	884.1	1,096	1,102	1,140	1,604	1,283
Short-Term Debt	478.5	472.24	287.58	76	229.18	168.18
Current Portion of Leases	64.8	65.1	63.83	43.78	82.96	56.21
Current Income Taxes Payable	459.8	323.29	145.54	108.45	204.18	185.86
Other Current Liabilities	1,316	1,419	630.65	1,133	624.44	633.02
Total Current Liabilities	5,088	5,096	3,914	4,427	5,538	4,853
Long-Term Leases	121.1	146.2	139.83	132.06	108.73	131.94
Pension & Post-Retirement Benefits	314.6	300.98	278.11	251.91	222.94	261.28
Long-Term Deferred Tax Liabilities	-	0.6	1.05	2.14	-	-
Total Liabilities	5,523	5,544	4,333	4,813	5,870	5,247
Common Stock	435.9	435.94	435.94	435.94	435.94	435.94
Additional Paid-In Capital	2,305	2,305	2,305	2,305	2,305	2,305
Retained Earnings	8,935	8,353	7,830	7,210	6,655	5,766
Comprehensive Income & Other	-1,169	-878.11	-693.31	-648.11	-618.9	-503.97
Total Common Equity	10,507	10,215	9,877	9,302	8,777	8,003
Minority Interest	0.1	0.03	0.08	0.02	0.07	22.3
Shareholders' Equity	10,507	10,215	9,877	9,302	8,777	8,025
Total Liabilities & Equity	16,030	15,759	14,210	14,115	14,646	13,272
Total Debt	664.4	683.54	491.24	251.84	420.87	356.33
Net Cash (Debt)	3,973	3,960	3,367	2,470	2,378	2,184
Net Cash Growth	15.76%	17.63%	36.31%	3.86%	8.89%	273.44%
Net Cash Per Share	4.54	4.54	3.86	2.83	2.73	2.50
Filing Date Shares Outstanding	876.23	871.87	871.87	871.87	871.87	871.87
Total Common Shares Outstanding	876.23	871.87	871.87	871.87	871.87	871.87
Working Capital	6,555	6,256	6,312	5,563	5,052	4,448
Book Value Per Share	11.99	11.72	11.33	10.67	10.07	9.18
Tangible Book Value	9,181	8,920	8,558	7,984	7,447	6,650
Tangible Book Value Per Share	10.48	10.23	9.82	9.16	8.54	7.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.